
Aureka Biotechnologies is a biotech startup focused on transforming pharmaceutical discovery through a digital biology and AI platform. Their technology enables rapid, efficient discovery of high-value protein therapeutics, targeting previously difficult mechanisms and reducing time and cost. The company operates a best-in-class platform ecosystem for immunotherapeutic discovery, partnering with pharma and biotech firms to design novel antibody therapeutics. Their interdisciplinary team combines expertise in synthetic biology, single-cell technologies, data science, computational biology, and deep learning to innovate continuously in therapeutic discovery.

Aureka Biotechnologies is a biotech startup focused on transforming pharmaceutical discovery through a digital biology and AI platform. Their technology enables rapid, efficient discovery of high-value protein therapeutics, targeting previously difficult mechanisms and reducing time and cost. The company operates a best-in-class platform ecosystem for immunotherapeutic discovery, partnering with pharma and biotech firms to design novel antibody therapeutics. Their interdisciplinary team combines expertise in synthetic biology, single-cell technologies, data science, computational biology, and deep learning to innovate continuously in therapeutic discovery.
Founded: 2023
Headquarters: Laguna Hills, California
Focus: Digital biology and AI platform for protein and immunotherapeutic discovery
Notable tech: High-throughput single-cell screening, synthetic biology, generative AI
Reported funding: $10M seed (reported); total funding records list $33,370,000
Drug discovery for protein- and antibody-based therapeutics, including immunotherapies and complex multi-objective design challenges.
2023
Biotechnology
$10,000,000
Dealroom and Crunchbase entries report a $10M seed; investor listings show K2VC and NRL Capital as lead investors.
“5Y Capital; BioTools Innovator; K2VC; NRL Capital; Newlife Capital; Qiming Venture Partners”
| Company |
|---|